BioCentury
ARTICLE | Product R&D

All-in-one viruses

How PsiOxus is building a gene therapy cancer platform on its oncolytic virus

July 12, 2018 6:52 PM UTC

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells wherever they reside.

The idea behind the company’s T-SIGn platform is that by delivering to tumor cells genes that interplay with immuno-oncology pathways, the company can either weaponize the cells to modify the tumor microenvironment or alter their properties to make them more vulnerable to immune attack...

BCIQ Company Profiles

Akamis Bio Ltd.